Wednesday, June 16, 2004 12:07:49 PM
J.M. Dutton & Associates Announces Investment Opinion: DNAPrint genomics Speculative Buy Rating in Initiating Coverage by Dutton & Associates - Tuesday June 8, 10:30 am ET
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--June 8, 2004--J.M. Dutton & Associates initiates coverage of DNAPrint genomics (OTCBB:DNAP - News) with a Speculative Buy rating. The 22-page report by J.M. Dutton senior analyst Sherry Grisewood, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Multex, and other leading financial portals.
The cost of enrollment in our one-year continuing research program is US $28,000 prepaid before commencement of our research activities. We received $28,000 from the Company for coverage for the year, and do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies.
-----
Curious why the SEC doesn't feel that this was disclosure enough and why DNAP was listed along with the others...?
God Bless and take care,
Robert
FEATURED Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • Jul 29, 2024 9:07 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM